ARS Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative, needle-free treatments for severe allergic reactions, including anaphylaxis. The company's primary product is neffy® (epinephrine nasal spray), which represents the first and only FDA-approved needle-free emergency treatment for Type I allergic reactions. Utilizing its proprietary Intravail® absorption enhancement technology, neffy delivers therapeutic doses of epinephrine intranasally, offering a highly portable, reliable, and non-invasive alternative to traditional intramuscular auto-injectors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the direct sales force from 106 representatives at the end of 2025 to 148 representatives in early 2026 to increase prescribing depth and call frequency with high-volume allergists and pediatricians.
Expected impact: Aims to accelerate neffy's market share growth, deepen physician adoption, and capture a larger share of the $2 billion annual U.S. epinephrine market.
Implementing a $199 retail pharmacy cash option and point-of-sale programs to reduce abandoned prescriptions and simplify the purchasing process for patients facing high insurance quotes.
Expected impact: Designed to improve prescription fill and adherence rates, re-engage lapsed patients, and convert untreated patients.
Securing international regulatory approvals and executing commercial rollouts of neffy (EURneffy / 优敏速) in key global markets through a network of regional partners.
Expected impact: Establishes a global footprint for the needle-free epinephrine spray, generating high-margin royalty and supply revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
ALK is a global leader in allergy immunotherapy. Under a November 2024 agreement, ALK holds exclusive rights to commercialize neffy in Europe, Canada, the UK, and other territories outside the U.S. In May 2025, the partnership was extended to co-promote neffy to up to 9,000 pediatricians in the U.S.
Terms: For the ex-U.S. license, ARS received a $145 million upfront payment and is eligible for up to $310 million in additional regulatory and sales milestones, plus tiered double-digit royalties. For the U.S. co-promotion, ARS compensates ALK for sales force costs via a quarterly base fee, with ALK eligible for performance-based payments starting in year two.
Provides Pediatrix with exclusive rights to commercialize neffy in China for severe allergic reactions and chronic spontaneous urticaria.
Terms: ARS received a $4 million regulatory milestone following China's approval of neffy 2 mg in December 2025, and is eligible for up to $80 million in sales milestones plus tiered low double-digit royalties on net sales.